NCT01122407 is a Phase 1 clinical trial of L-NMMA in Obesity, sponsored by Vanderbilt University Medical Center.

Who is sponsoring NCT01122407?

NCT01122407 is sponsored by Vanderbilt University Medical Center.

What drugs are being tested in NCT01122407?

Interventions in NCT01122407: L-NMMA, Trimethaphan.

What condition does NCT01122407 study?

NCT01122407 studies Obesity, Hypertension.

Is NCT01122407 still recruiting?

NCT01122407 is currently completed. Last updated 16 January 2017.

Last reviewed 2017-01-16 · How we verify

NCT01122407

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Obesity, Hypertension in African American Women, Neuro-metabolic Mechanism

Completed Phase 1 Last updated 16 January 2017

What this trial tests

Phase 1 trial testing L-NMMA in Obesity in 34 participants. Completed in 1 November 2016.

Timeline

1 January 2010

Primary endpoint
1 November 2016

1 November 2016

Quick facts

Lead sponsor	Vanderbilt University Medical Center
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Enrollment	34
Start date	1 January 2010
Primary completion	1 November 2016
Estimated completion	1 November 2016
Sites	1 location across United States

Drugs / interventions tested

L-NMMA — full drug profile →
Trimethaphan — full drug profile →

Conditions studied

Obesity — all drugs for Obesity →
Hypertension — all drugs for Hypertension →

Sponsor

Vanderbilt University Medical Center

Who can join

Adults 30 to 50, female only, with Obesity or Hypertension. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

change in systolic blood pressure in response to trimethaphan, as a measurement of the tonic sympathetic contribution to blood pressure.
Time frame: 30 minutes after initiation of Trimethaphan infusion
Will infuse trimethaphan for until complete autonomic blockade is achieved.

Sponsor's own description

The overall goal of this proposal is to determine the autonomic and nitric oxide contribution in the pathogenesis of hypertension and insulin resistance in obese African American women. For this purpose we will use two non-FDA approved drugs: Trimethaphan IND# 63826 Approval date 12/20/2001 L-NMMA IND# 41735 Approval date 09/1993

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Hypertension in Obese Black Women is Not Caused by Increased Sympathetic Vascular Tone.
Marinos A, Gamboa A, Celedonio JE, Preheim BA, et al · · 2017 · cited 14× · PMID 29151035 · DOI 10.1161/jaha.117.006971
Complete autonomic blockade reveals nitric oxide contribution to blood pressure regulation in obese Black women.
Rahman S, Gamboa A, Saleem M, Kulapatana S, et al · · 2024 · PMID 39090323 · DOI 10.1007/s10286-024-01050-3

Verify or expand the search:

Other trials of L-NMMA

Trials testing the same drug.

NCT05660083 — Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) · Phase 2 · recruiting
NCT03066115 — Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation · Phase 1 · withdrawn
NCT03236935 — Phase Ib of L-NMMA and Pembrolizumab · Phase 1 · completed
NCT00508989 — Niacin to Improve Blood Flow in People With Sickle Cell Disease · Phase 2 · completed
NCT00327080 — Sildenafil to Treat HIV-Associated Pulmonary Hypertension · Phase 1 · terminated

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other Vanderbilt University Medical Center trials

Trials by the same sponsor.

NCT07005037 — Swallowing Impairments in ICU Survivors and Community-Dwelling Adults · not yet recruiting
NCT07527273 — Cognitive Enhancement in Recurrent Depression (The COG-D-R Study) · NA · not yet recruiting
NCT07295288 — Botox Injections in Non-Cranial Nerve VII Innervated Muscles for Facial Synkinesis · Phase 4 · not yet recruiting
NCT07431541 — Topical Carboxytherapy Paste Following Microneedling · Phase 1, PHASE2 · not yet recruiting
NCT07224711 — The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01122407 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vanderbilt University Medical Center
Last refreshed: 16 January 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01122407.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing